Very early prediction of response to HCV treatment with PEG‐IFN‐alfa‐2a and ribavirin in HIV/HCV‐coinfected patients

摘要: Summary.  The objective of this study was to find very early viral kinetic markers predict nonresponse hepatitis C virus (HCV) therapy in a group human immunodeficiency (HIV)/HCV-coinfected patients. Twenty-six patients (15 HCV genotype-1 and 11 genotype-3) were treated with 48-week regimen peginterferon-alfa-2a (PEG-IFN) (180 μg/week) weight-based ribavirin (11 mg/kg/day). Samples collected at baseline; 4, 8, 12, 18, 24, 30, 36 42 h; days 2, 3, 7, 15, 22, 29, 43 57 then weekly monthly. Five discontinued treatment. Seven (27%) achieved sustained virological response (SVR). Nadir RNA levels observed 1.6 ± 0.3 days after initiation therapy, followed by 0.3- 12.9-fold rebound until the administration second dose PEG-IFN, which not associated SVR or genotype. A decline <1.19 log for <0.97 log genotype-3, 2 days starting had negative predictive value (NPV) 100% SVR. day 2 similar positive as rapid week 4. In addition, second-phase slope (i.e., measured from 29) <0.3 log/week NPV = 100% We conclude that first-phase (<0.3 log/week) are excellent predictors nonresponse. Further studies needed validate these parameters on-treatment prognosticators HIV.